CClinicalTrials.gg
Not yet recruitingNCT06678867P5AUpdated Mar 27, 2025

The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours

A Phase 2 interventional study of 5-ALA (Gliolan) in Brain Tumor, sponsored by University College, London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by University College, London · Phase 2, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jun 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Study summary

The aim of the study is to examine the safety and feasibility of using 5-ALA in children who have MRI scans showing an aggressive looking brain tumour. It will also study if 5-ALA can help the surgeon achieve maximal tumour removal and discriminate between normal brain tissue and tumour.

Patients will be between 3-18 years (inclusive) and all patients will receive 5-ALA 3-6 hours prior to resection surgery.

02

Conditions studied

  • Brain Tumor

Browse trials for

Keywords

  • Ependymoma
  • Glioma
  • Paediatric
  • 5-ALA
  • Brain tumour
03

In context

Brain Neoplasms

1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's planned enrollment of 80 is above the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

University College, London is the lead sponsor of 632 studies on the registry; 145 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Magnetic Resonance Imaging confirmation of diagnosis consistent with either: primary presentation of high grade brain tumour OR patient relapsing with previously confirmed ependymoma or high-grade glial tumour
  • Tumours will be either intrinsic supratentorial or infratentorial / posterior fossa, non-brainstem, tumours
  • Patient is appropriate for maximal safe resection of tumour, based on Investigator and Multidisciplinary Team judgement
  • 3 - 18 years inclusive
  • Adequate liver and kidney function

    • creatinine - less than one and a half times the upper limit of normal.
    • haemoglobin above the lower limit of normal
    • Alanine transferase or Aspartate transferase less than twice the upper limit of normal (if both performed, then both results must be lower than twice the upper limit of normal
    • bilirubin lower than one and a half times the upper limit of normal
  • Normal Coagulation profile

    o Prothombin Time, Activated Partial Prothombin Time and Thrombin Time all within normal limits

  • Urine porphyrin - Test to be completed and sent for analysis
  • Blood pressure lower than or equal to the upper limit of normal
  • Negative pregnancy test in women of childbearing potential*
  • Informed Consent *A positive pregnancy test that is suspected to be due to the location of the tumour is to be queried with the TMG prior to registration of the patient

Exclusion criteria

Exclusion Criteria:

  • Patients with low grade tumours (either radiological or histological diagnosis)
  • Patient is appropriate for biopsy only, based on Investigator and MDT judgement
  • Known history (including family history) of porphyria
  • Hypersensitivity to the active substance or to porphyrins
  • History of light sensitivity reactions
  • Pregnant or breastfeeding women
05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Patients with high grade brain tumours

    This is a single-arm study with two cohorts

    Drug: 5-ALA (Gliolan)

Interventions

  • Drug5-ALA (Gliolan)

    Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery

06

What researchers measure

Primary outcomes

  1. Cohort 1: Complete resection rate and fluorescence rate of supratentorial instrinsic high grade brain tumours. Cohort 2: Fluorescence rate of infratentorial tumours.

    Timeframe between informed consent and surgery

    Time frame: Two weeks

07

Study locations

1 site
  • Nottingham Children's Hospital
    Nottingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Following data protection guidance

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678867
Lead sponsor
University College, London
Collaborators
University of Nottingham
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Mar 25, 2025 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 27, 2025

Study contacts

Paed 5-ALA Trial Manager
Contact
ctc.paed5-ala@ucl.ac.uk
020 7679 9860

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion